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ABSTRACT
Development of cribriform morphology (CM) heralds malignant change in human 
colon but lack of mechanistic understanding hampers preventive therapy. This study 
investigated CM pathobiology in three-dimensional (3D) Caco-2 culture models of 
colorectal glandular architecture, assessed translational relevance and tested effects 
of 1,25(OH)2D3, the active form of vitamin D. CM evolution was driven by oncogenic 
perturbation of the apical polarity (AP) complex comprising PTEN, CDC42 and PRKCZ 
(phosphatase and tensin homolog, cell division cycle 42 and protein kinase C zeta). 
Suppression of AP genes initiated a spatiotemporal cascade of mitotic spindle 
misorientation, apical membrane misalignment and aberrant epithelial configuration. 
Collectively, these events promoted “Swiss cheese-like” cribriform morphology (CM) 
comprising multiple abnormal “back to back” lumens surrounded by atypical stratified 
epithelium, in 3D colorectal gland models. Intestinal cancer driven purely by PTEN-
deficiency in transgenic mice developed CM and in human CRC, CM associated with 
PTEN and PRKCZ readouts. Treatment of PTEN-deficient 3D cultures with 1,25(OH)2D3 
upregulated PTEN, rapidly activated CDC42 and PRKCZ, corrected mitotic spindle 
alignment and suppressed CM development. Conversely, mutationally-activated KRAS 
blocked 1,25(OH)2D3 rescue of glandular architecture. We conclude that 1,25(OH)2D3 
upregulates AP signalling to reverse CM in a KRAS wild type (wt), clinically predictive 
CRC model system. Vitamin D could be developed as therapy to suppress inception or 
progression of a subset of colorectal tumors.
INTRODUCTION
Oncogenic perturbation of cell-cell interactions and 
hierarchical, three-dimensional (3D) tissue organization 
characterizes cancer development [1] and progression [2]. 
Cribriform morphology (CM) is commonly viewed as a 
histopathological correlate of malignant transformation 
in human colon [3], detectable in malignant polyps [4] 
and early invasive colorectal cancer (CRC) [5]. CM 
has a “Swiss-cheese - like” histological appearance, 
characterized by multiple abnormal lumens surrounded 
by stratified malignant epithelium [6]. While CM 
pathobiology remains unclear, lumen formation and 
epithelial configuration are governed by mitotic spindle 
orientation [7, 8].
Spindle alignment is controlled by the apical polarity 
complex including PTEN, CDC42, PRKC and PARD 
genes [9, 10]. PTEN is a tumor suppressor that coordinates 
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the CDC42-PRKCZ-PARD complex [11, 12] and regulates 
spindle orientation in nonpolarized cultured cells [13]. 
PRKCZ spatially regulates PARD3 that cooperates with 
the heterotrimeric G protein subunit GNAI3 (guanine 
nucleotide binding protein alpha inhibiting activity 
polypeptide 3; also known as Gαi3) to localize the spindle 
orientation protein, G-protein signalling modulator 2 
(GPSM2; also known as LGN) [14]. PARD3 directs the 
orientation of pulling forces linked through GPSM2 to 
spindle microtubules for appropriate spindle alignment 
[14]. Perturbation of this machinery drives transition to 
dysplasia in Drosophila [15] but effects on colorectal 
glandular architecture remain unclear. 
Components of the apical polarity complex 
including PTEN [16] and PRKCZ [17] can be enhanced 
by vitamin D (Vit-D) treatment. This secosteroid also 
promotes rapid calcium (Ca2+) signalling [18] that 
activates CDC42 [19, 20] and controls spindle microtubule 
dynamics [21]. Vit-D influences molecular to multicellular 
scales of tissue organization [22-24] and suppresses CRC 
progression [25, 26]. Conversely, mutationally-activated 
KRAS may inhibit Vit-D growth control [27, 28] by 
unclear mechanisms. 
In this study, we investigated CM pathobiology 
using three-dimensional (3D) organotypic CRC culture 
model systems. We tested 1,25(OH)2D3 treatment and 
investigated effects of mutationally-activated KRAS. To 
investigate translational relevance of our experimental 
findings, we conducted histologic, immunohistochemical 
and/or RNA in situ hybridization assays in murine and 
human tumors. 
RESULTS
PTEN deficiency induces mitotic spindle 
misorientation, epithelial stratification and 
cribriform morphology
The tumor suppressor PTEN regulates CDC42 and 
apical PRKCZ activity [11, 12] that have a mechanistic 
role in spindle orientation, lumen formation and 3D 
epithelial morphology [7, 9, 29]. Downstream of PTEN, 
CDC42 promotes recruitment and activation of PRKCZ at 
the apical domain that localizes PARD3 [30] to a nascent 
apical junctional complex required for spindle alignment 
[14]. Here we show that PTEN-deficiency induces spindle 
misorientation (Figure 1A, 1B), epithelial stratification 
and multilumen formation in Caco-2 ShPTEN glandular 
structures [glands] (Figure 1C [i-iii]) consistent with 
CRC cribriform morphology [CM] (Figure 1C [iv]). 
Epithelial stratification was typically focal in early 
developing glands, becoming organised around multiple 
abnormal lumens at later stages (Figure 1C [i-iii]). Focal 
stratification without multilumen formation was observed 
in some late stage Caco-2 ShPTEN glands (Supplementary 
Figure S1A). Schematics for epithelial stratification and 
cribriform morphogenesis are shown (Figure 1D, 1E). 
Epithelial stratification in Caco-2 and Caco-2 ShPTEN 
glands is summarised in Figure 1F.
Functional readout of PRKCZ activity at the 
apical domain can be provided by signal intensity of 
apical phospho-PRKCZ (p-PRKCZ) [9] or SLC9A3R1 
[Solute carrier family 9, subfamily A (NHE3, cation 
proton antiporter 3), member 3 regulator 1; also known 
as NHERF-1 (Na+/H+ exchange regulatory factor 1)] 
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Figure 1: A. PTEN knockdown misorientates the mitotic spindle. Caco-2 and Caco-2 ShPTEN gland cultures at 4 days. DAPI (blue), 
p-PRKCZ (red) and anti-α -tubulin (green) were used as markers of nuclear DNA, apical PRKCZ activity and spindle microtubules 
respectively. Mitotic spindle orientation (double headed solid white arrow) is positioned approximately perpendicular to the Caco-2 gland 
lumen but is misorientated in Caco-2 ShPTEN glands. Scale bar 20 μm. B. Summary angles between spindle midpoints and gland lumens. 
Caco-2 - 65.5 ± 3.70 vs Caco-2 ShPTEN - 34.9 ± 5.90; (p < 0.01; ANOVA). C. CM evolution in Caco-2 ShPTEN glands. At (i) 4 days, the 
mitotic spindle (anti-α-tubulin; green) is misorientated relative to gland centres (double headed white arrow), accompanied by misalignment 
of the apical membrane (AM; red; fine interrupted white arrows). At (ii) 8 days, secretion-driven expansion of ectopic AM forms multiple 
abnormal lumens (solid white arrows), accompanied by epithelial stratification (broad interrupted white arrows). These phenomena induce 
well-formed cribriform morphology at (iii) 12 days, characterized by multiple gland lumens surrounded by stratified epithelium (broad 
interrupted white arrows). Scale bar 20 μm. These glandular architecture alterations are evocative of cribriform morphology in human 
CRC (iv; H&E section of human CRC showing a glandular structure with multiple aberrant lumens, surrounded by abnormal stratified 
epithelium [broad interrupted white arrows]). D. Schematic of spindle orientation and epithelial configuration. During mitosis, the plane 
of cell cleavage (double headed black arrow - interrupted line) lies perpendicular to the spindle midpoint. The mitotic spindle is orientated 
(MSO) (green microtubules/black centrosomes) approximately perpendicular (┴) to the cell long axis. With this configuration, cell division 
generates an epithelial monolayer within glands, with cells linked by apical junctions (orange). Apical membranes (AM; red) face a 
central lumen. When mitotic spindle orientation (MSO) is parallel (═) to the cell long axis cell division generates stratified epithelium 
(light brown).  E. Schematic of CM evolution. Spindle misorientation (i) induces epithelial stratification (light brown) and AM (red) 
misalignment. (ii) Secretion driven expansion of ectopic AM leads to multilumen formation [7]. (iii) Collectively, these phenomena induce 
CM (iv). F. Summary effects of PTEN knockdown on epithelial stratification. Values shown indicate % glands with any stratification (Caco-
2 - 22.7 ± 7.5% vs Caco-2ShPTEN - 71.3 ± 12.6%; p < 0.03; ANOVA).  G. PTEN knockdown suppresses CDC42/PRKCZ and promotes 
PARD3 mislocalization. CDC42-GTP, apical p-PRKCZ immunofluorescence and PARD3 localization are shown. PARD3 localizes to apical 
junction regions in Caco-2 glands. In Caco-2 ShPTEN glands low CDC42 activity, low apical p-PRKCZ and PARD3 mislocalization 
associate with CM. Multilumen formation indicated by solid white arrows. Scale bar 20 μm. H. Summary effects of PTEN knockdown on 
CDC42 and p-PRKCZ. Values represent fold differences in CDC42-GTP and apical p-PRKCZ intensities respectively in Caco-2 ShPTEN 
vs Caco-2 glands; CDC42-GTP - 0.40 ± 0.03; p-PRKCZ - 0.45 ± 0.04; p < 0.01 ANOVA). 
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[12]. In accord with PTEN regulation of the CDC42/
PRKCZ/PARD complex, we show low CDC42-GTP 
(guanine triphosphate) immunofluorescence, reduced 
apical p-PRKCZ signal intensity (Figure 1G, 1H) and 
displacement of PARD3 from the subapical domain 
in PTEN-deficient Caco-2 ShPTEN glands (Figure 
1G). Caco-2 shPTEN glands were more cellular 
(Supplementary Figure S1B) with greater maximum 
surface area (Supplementary Figure S1C) than Caco-
2 glands, consistent with impairment of PTEN 
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Figure 2: A. Effects of 1,25(OH)2D3 treatment on VDR expression. (i) Treatment effects on vitamin D receptor (VDR) expression in 
Caco-2 and Caco-2 ShPTEN cells. (ii) Summary densitometry values represent fold expression changes relative to VO treated Caco-2 
cells (Caco-2 1,25(OH)2D3 - 1.47 ± 0.04; Caco-2 ShPTEN VO - 0.68 ± 0.04; Caco-2 ShPTEN 1,25(OH)2D3 1.40 ± 0.6; p < 0.01; ANOVA). 
B. Effects of 1,25(OH)2D3 treatment on PTEN and CDC42-GTP. (i) Treatment effects on CDC42-GTP and PTEN in Caco-2 and Caco-
2 ShPTEN cells. Summary densitometry values for (ii) CDC42-GTP and (iii) PTEN represent fold expression changes relative to VO 
treated Caco-2 cells (CDC42-GTP - Caco-2 1,25(OH)2D3 - 2.0 ± 0.14;Caco-2 ShPTEN VO - 0.68 ± 0.04; Caco-2 ShPTEN; 1,25(OH)2D3 
- 1.50 ± 0.06; Caco-2 1,25(OH)2D3 - 1.67 ± 0.09; Caco-2 ShPTEN VO - 0.47 ± 0.044; Caco-2 ShPTEN 1,25(OH)2D3 - 1.3 ± 0.06; p < 
0.01; ANOVA).   C. 1,25(OH)2D3 treatment upregulates apical polarity signalling (p-PRKCZ and SLC9A3R1). Apical p-PRKCZ (red) and 
SLC9C3R1 (green) signal intensities in Caco-2 glands after treatment (VO - top row vs 1,25(OH)2D3 - bottom row). Scale bar 20 μm. D. 
Summary treatment effects on (i) apical p-PRKCZ and (ii) SLC9A3R1. Values represent fold changes of apical p-PRKCZ (3.3 ± 0.37) and 
SLC9A3R1 (2.29 ± 0.18) signal intensities after 1,25(OH)2D3 vs VO control; p < 0.01; ANOVA). E. 1,25(OH)2D3 treatment restores spindle 
orientation in Caco-2 ShPTEN glands . Treatment by vehicle only (VO; top panel) or 1,25(OH)2D3 (bottom panel).  Imaging by DAPI (blue) 
and anti-α-tubulin (green). Spindle orientation indicated by double-headed white arrows in Merge images. Scale bar 20 μm. F. Summary 
effects of 1,25(OH)2D3 treatment on spindle orientation. Summary spindle angles in Caco-2-ShPTEN glands after treatment (VO - 35 ± 5.90 
vs 1,25(OH)2D3 - 63 ± 4.50; p < 0.01; ANOVA). G. 1,25(OH)2D3 treatment suppresses development of cribriform morphology. Epithelial 
stratification (broad interrupted white arrow) and multiple lumens (solid white arrows) in Caco-2ShPTEN glands after treatment by VO vs 
1,25(OH)2D3. Scale bar 20 μm. H. 1,25(OH)2D3 treatment suppresses epithelial stratification. Caco-2 - VO - 22.6 ± 7.5%; 1,25(OH)2D3 - 
25.0 ± 7.0%; Caco-2 ShPTEN - VO - 71.3 ± 12.6%; 1,25(OH)2D3 - 29.6 ± 7.6%; Two way ANOVA - p < 0.02 for effects of cell type and p 
< 0.04 for cell type-treatment interaction. 
Oncotarget7www.impactjournals.com/oncotarget
Oncotarget8www.impactjournals.com/oncotarget
Figure 3: A. Timecourse of 1,25(OH)2D3 modulation of CDC42-GTP and PTEN. GAPDH loading control. B. Summary effects of 
1,25(OH)2D3 on CDC42-GTP. Densitometry values are fold differences of CDC42-GTP levels in Caco-2 cells over VO control (1,25(OH)2D3 
- 5 mins - 1.6 ± 0.09; 30 mins - 1.55 ± 0.05; 24h - 1.59 ± 0.12; p<0.01; ANOVA). C. Summary effects of 1,25(OH)2D3 on PTEN. Densitometry 
values are fold differences of PTEN levels in Caco-2 cells over VO control (1,25(OH)2D3 5 mins - 1.05 ± 0.03; 30 mins - 1.0 ± 0.05; 24h - 
1.46 ± 0.07; p<0.01 for 24hr ; ANOVA). D. 1,25(OH)2D3 activation of CDC42 is PTEN-independent. Effects of 1,25(OH)2D3 treatment on 
CDC42-GTP levels in PTEN+/+ and PTEN-/- HCT116 cells. VDR indicates biological responsiveness and GAPDH used as loading control. 
E. Summary effects of 1,25(OH)2D3 on CDC42-GTP in PTEN+/+ and PTEN-/- HCT116 cells. Values shown are fold differences over VO 
control (PTEN +/+ HCT116 1,25(OH)2D3 - 1.63 ± 0.09; PTEN -/- HCT116 VO - 0.67 ± 0.07; PTEN -/- HCT116 1,25(OH)2D3 - 1.41 ± 0.04; 
p<0.01 ANOVA). F. Inhibition of PRKCZ suppresses 1,25(OH)2D3 rescue of Caco-2 ShPTEN gland morphology. Apical p-PRKCZ and 
CTNNB1 were used as apical and basolateral membrane markers respectively. Multilumen formation indicated by white solid arrows in 
Merge images. Top row - VO; Second row -1,25(OH)2D3; Third row PRKCZ pseudosubstrate inhibitor (PRKCZI); Bottom row combined 
1,25(OH)2D3/PRKCZI treatment. Scale bar 20 μm. G. Summary treatment effects on single lumen formation in Caco-2 ShPTEN glands. 
Values shown are fold differences over VO control (1,25(OH)2D3 - 2.01 ± 0.1; PRKCZI - 0.59 ± 0.07; 1,25(OH)2D3/PRKCZI - 0.84 ± 0.07; 
p<0.01 for 1,25(OH)2D3 vs VO; ANOVA).
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antiproliferative activity. SiRNA knockdown of PTEN in 
SK-CO-15 CRC cells (Supplementary Figure S1D) also 
induced cribriform architecture with multiple aberrant 
lumens (Supplementary Figure S1E, S1F) and increased 
cellularity, in 3D cultures (Supplementary Figure S1G). 
1,25(OH)
2
D
3
 upregulates PTEN/CDC42/ PRKCZ 
signalling to control gland morphology
1,25(OH)2D3 treatment enhanced vitamin D 
receptor (VDR) expression, perinuclear and nuclear 
VDR localization in Caco-2 and Caco-2ShPTEN cells, 
indicating biological responsiveness of the model 
system (Figure 2A; Supplementary Figure S2A, S2B). 
Treatment also increased PTEN expression (Figure 2B) 
and activation of CDC42 (Figure 2B). 1,25(OH)2D3 
treatment enhanced apical p-PRKCZ and SLC9A3R1 
signal intensities in Caco-2 glands (Figure 2C, 2D) and 
restored spindle orientation (Figure 2E, 2F), formation 
of epithelial monolayers within glands (Figure 2G, 2H) 
and single lumen formation at progressive stages of Caco-
2 ShPTEN gland development (Supplementary Figure 
S2C, S2D). Continuous 1,25(OH)2D3 treatment sustained 
long term (20 days) rescue of Caco-2 ShPTEN gland 
morphology (Supplementary Figure S2E, S2F) while 
cessation of treatment at 4 days induced reversal to CM 
(Supplementary Figure S2G, S2H). 1,25(OH)2D3 treatment 
also suppressed Caco-2 ShPTEN gland cellularity 
(Supplementary Figure S2I). Hence, 1,25(OH)2D3 targets 
spindle regulatory machinery to control 3D colorectal 
gland morphology. 
1,25(OH)
2
D
3
 rescues defective morphology of 
PTEN-deficient glands by targeting CDC42/
PRKCZ crosstalk
1,25(OH)2D3 initiates rapid nongenomic biological 
responses, in addition to transcriptional effects on target 
genes [31].To identify principal 1,25(OH)2D3 - responsive 
effectors within the PTEN/CDC42/PRKCZ complex, 
we conducted timescale, transfection and treatment 
studies. We found that 1,25(OH)2D3 treatment activated 
CDC42 within 5 minutes but only upregulated PTEN 
by 24 hrs (Figure 3A-3D). Furthermore, we showed 
that 1,25(OH)2D3 upregulated CDC42-GTP in both 
PTEN +/+ and PTEN -/- HCT116 cells (Figure 3D, 3E). 
Hence, 1,25(OH)2D3 upregulates PTEN but can also 
activate CDC42 by PTEN-independent mechanisms. 
To disrupt morphogenesis of Caco-2 glands, we stably 
transfected cells with dominant negative (DN) CDC42 
(Supplementary Figure S3A, S3B) or treated cultures 
with a PRKCZ pseudosubstrate inhibitor (PRKCZI) 
(Supplementary Figure S3C, S3D). Aberrant gland 
morphology resulting from DN CDC42 transfection or 
PRKCZI treatment could not be reversed by 1,25(OH)2D3 
treatment (Supplementary Figure S3A-S3D). Furthermore, 
rescue of Caco-2 ShPTEN gland morphology by 
1,25(OH)2D3 treatment was blocked by PRKCZI treatment 
(Figure 3F, 3G). These findings show that 1,25(OH)2D3 can 
rescue aberrant morphology of Caco-2 ShPTEN glands by 
targeting CDC42/PRKCZ crosstalk. 
1,25(OH)
2
D
3
 activates CDC42/PRKCZ signalling 
through Ca2+ flux
1,25(OH)2D3 promotes rapid VDR-dependent Ca2+ 
flux [18], mediated through L-type voltage-dependent 
calcium channels (LTVDCCs) [32] and CaM-KII activity 
[32]. Ca2+ flux and/or calcium-calmodulin dependent 
protein kinase (CaM-KII) activity can enhance CDC42-
GTP polarity signalling [19, 20]. In this study, Caco-2 
glands expressed LTVDCCs predominantly at basolateral 
membranes (Figure 4A). 1,25(OH)2D3 treatment increased 
intracellular Ca2+ concentration in Caco-2 cells (Figure 
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Figure 4: A. Expression of L-type voltage-dependent Ca2+ channels (LTVDCC) in Caco-2 glands. DAPI, p-PRKCZ and Cav 1.3 were 
used as markers of nuclear DNA, apical PRKCZ activity and the β-subunit of the L-type voltage-dependent Ca2+ channel, respectively. 
Expression of the β-subunit of LTVDCCs is predominantly basolateral in polarized epithelium [46]. B. 1,25 (OH)2D3 promotes Ca2+ flux 
I. Representative fluorescence images of Caco-2 cells loaded with fluo-4AM before (i) and after (ii) exposure to 1,25 (OH)2D3 (100nM). 
An increase in intracellular Ca2+ is shown by an increase in fluorescence intensity.II. Intensity-time plot of the effect of 1,25 (OH)2D3.
III. Summary bar chart of fluorescence amplitude evoked by 1,25 (OH)2D3 (n = 13 cells) or the Ca2+-ionophore, ionomycin (1µM, n = 
27 cells; positive control). C. Calcium channel blockade impedes morphogenesis. (i) Caco-2 gland morphogenesis at 4 days after VO 
(top row), NF (second row) or 1,25(OH)2D3/NF combined treatment (bottom row). Multiple lumen formation indicated by solid white 
arrows in Merge images. Scale bar - 20 μM.(ii) Summary values represent fold change of single lumen formation relative to VO control 
(NF - 0.60 ± 0.06; 1,25(OH)2D3/NF in combination - 0.70 ± 0.054; p < 0.01 ANOVA). D. CaM-KII inhibition impedes morphogenesis. (i) 
Caco-2 gland morphogenesis at 4 days after VO (top row), KN-93 (second row) or 1,25(OH)2D3/KN-93 combined treatment (bottom row). 
Aberrant lumens or ectopic AM foci (indicated by solid or fine interrupted white arrows respectively in Merge). Scale bar - 20 μM. (ii) 
Summary values represent single lumen formation relative to VO control (KN-93 - 0.50 ± 0.06; 1,25(OH)2D3/KN-93 - 0.60 ± 0.062; p < 
0.01 ANOVA). E. VDR knockdown suppresses 1,25(OH)2D3 rescue of morphogenesis. Images show Caco-2 ShPTEN gland morphogenesis 
after SiRNA transfection and treatment, at 4 days of culture. Top 2 panels show effects of VO or 1,25(OH)2D3 treatment combined with non-
targeting (NT) SiRNA; bottom 2 panels - VO or 1,25(OH)2D3 treatment combined with VDR SiRNA. DAPI, p-PRKCZ and VDR imaging. 
Ectopic AM foci indicated by fine interrupted white arrows in Merge images. Scale bar 20 μM. F. Summary effects of VDR knockdown on 
1,25(OH)2D3 rescue of Caco-2 ShPTEN gland morphogenesis. Values shown represent fold differences of single lumen formation against 
Caco-2 ShPTEN glands treated by VO and transfected by NT SiRNA. NT SiRNA + 1,25(OH)2D3 - 1.77 ± 0.09; VDR SiRNA +VO  =  0.51 
± 0.04; VDR SiRNA + 1,25(OH)2D3  =  0.6 ± 0.06; p < 0.01; ANOVA. G. Calcium channel blockade impedes 1,25(OH)2D3 rescue of Caco-2 
ShPTEN gland morphogenesis. Treatments were VO (top panel), 1,25(OH)2D3 (second panel), NF (third panel), NF/1,25(OH)2D3 (fourth 
panel). Multiple lumens and ectopic AM without lumens indicated by solid and fine interrupted white arrows respectively in Merge images. 
Scale bar 20 μM. H. Summary treatment effects on single lumen formation in Caco-2 ShPTEN glands. Values are expressed as fold changes 
over VO control (1,25(OH)2D3 - 1.69 ± 0.03; NF - 0.59 ± 0.05; 1,25(OH)2D3/NF - 0.63 ± 0.03; p < 0.01 ANOVA). 
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Figure 5: A. KRASV12 impedes morphogenesis. Caco-2 (top 2 rows) or Caco-2 ShPTEN glands (bottom 2 rows) were transfected with 
empty vector (EV) or mutationally-activated KRAS (KRAS V12) and imaged for DAPI (blue), KRAS (green) and phospho-PRKCZ (red). 
KRAS V12 transfections in both cell types induced increased KRAS immunoreactivity and perturbed gland morphology, leading to solid 
cell-filled glands lacking a central lumen. Multilumen formation is observed in EV transfected Caco-2 ShPTEN glands, although this 
phenotype is suppressed by KRAS V12 transfection. B. Summary effects of KRAS V12 transfection on gland morphogenesis. Values shown 
represent % single lumen formation in Caco-2 vs Caco-2ShPTEN glands after EV or KRAS V12 transfection at 4 days of culture (Caco-2 - 
24.6 ± 0.88 (EV) vs 13.6 ± 1.2 (KRASV12); Caco-2 ShPTEN -15.3 ± 1.3 (EV) vs 11.0 ± 1.5 (KRASV12 ; p < 0.01;ANOVA). C. Summary 
effects of KRAS V12 transfection on apical p-PRKCZ intensity in Caco-2 glands. Results shown represent fold differences against EV 
transfected Caco-2 glands. KRAS V12 transfectants  =  0.495 ± 0.1; p < 0.01; Student’s t test. D. KRAS V12 suppresses 1,25(OH)2D3 rescue 
of gland morphology. Top panel - transfection by empty vector (EV) only and treatment by VO or 1,25(OH)2D3. Bottom panel - transfection 
with KRASV12, combined with VO or 1,25(OH)2D3 treatment. E. Summary effects of KRAS V12 vs EV transfection on 1,25(OH)2D3 rescue 
of Caco-2 ShPTEN gland morphology. Values shown represent single lumen formation after transfection and treatment at 4 days of culture, 
namely EV/VO - 15.3 ± 1.2 (VO); EV/1,25(OH)2D3 - 31.3 ± 1.46; KRAS/VO - 11.0 ± 1.15; KRAS/1,25(OH)2D3 - 15.67 ± 1.45; p < 0.001; 
Two Way ANOVA). 
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4BI, 4BII) and was compared against the Ca2+-ionophore, 
ionomycin as positive control (Figure 4BIII). SiRNA 
knockdown of VDR inhibited 1,25(OH)2D3-mediated 
CDC42 activation (Supplementary Figure S4A). Treatment 
of cells with the LTVDCC inhibitor nifedipine (NF) or the 
CaM-KII inhibitor KN-93 also suppressed 1,25(OH)2D3-
mediated CDC42 activation but did not affect PTEN 
levels (Supplementary Figure S4B, S4C). Treatment of 
developing Caco-2 glands with NF or KN-93 suppressed 
p-PRKCZ enrichment at apical domains, induced apical 
membrane misalignment and formation of multiple poorly 
formed lumens. These phenotypes in Caco-2 glands were 
not rescued by 1,25(OH)2D3 treatment (Figure 4C, 4D). 
Furthermore, 1,25(OH)2D3 rescue of morphogenesis in 
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Caco-2 ShPTEN glands was blocked by transfection 
with VDR SiRNA (Figure 4E, 4F) or cotreatment with 
NF (Figure 4G, 4H) or KN-93 (Supplementary Figure 
S4D, S4E). Taken together, these findings implicate VDR 
and Ca2+/CaM-KII signalling in 1,25(OH)2D3-mediated 
upregulation of CDC42/PRKCZ and reversal of cribriform 
morphology in PTEN-deficient colorectal glands.
Mutationally-activated KRAS suppresses 
1,25(OH)
2
D
3
 rescue of gland morphology
Because KRAS can suppress 1,25(OH)2D3 growth 
control [27], we investigated effects of mutationally-
activated KRAS V12 in our 3D Caco-2 and Caco-2 
Figure 6: A. PTEN-deficient intestinal tumors show cribriform morphology. A H&E section of a small intestinal carcinoma driven purely 
by PTEN-deficiency, shows CM. Scale bar 100 µM. B. Relationship between log transformed PTEN RNA levels and IHC scores in 309 
cores from 92 human CRCs (r = 0.325; p < 0.01; Pearson’s test). C. Apical SLC9A3R1 and cribriform morphology. Apical SLC9A3R1 
intensity and CM in all CRC cores (open bars; p < 0.01) and in the wt KRAS CRC subset (shaded bars; p = 0.014 ANOVA). D. PTEN RNA 
and cribriform morphology. PTEN RNA levels (log values) and CM in all CRC cores (open bars; p = 0.056) and in the KRAS wt CRC 
subset (shaded bars; p < 0.01) ANOVA. E. Apical SLC9A3R1 intensity and histological grade in all second cohort CRCs (n = 92). Grade 
I - 1.50 ± 0.34; Grade II - 1.15 ± 0.05; Grade III - 0.35 ± 0.1;p < 0.01;ANOVA. F. Apical SLC9A3R1 intensity and lymph node metastases 
in all second cohort CRCs (n = 92). No nodal involvement - 1.18 ± 0.06; invasion of 1-3 nodes - 0.87 ± 0.08; invasion of ≥ 4 nodes - 0.67 
± 0.13; p < 0.01; ANOVA.
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ShPTEN model systems. Transfection with KRAS V12 
inhibited lumen formation to yield glands that were cell-
filled and solid in appearance (Figure 5A, 5B), in accord 
with previous findings [33]. Furthermore, KRAS V12 
transfection suppressed apical localization of PRKCZ in 
Caco-2 glands (Figure 5A, 5C) and inhibited 1,25(OH)2D3 
rescue of Caco-2 ShPTEN gland morphology (Figure 5D, 
5E). Collectively, these findings show that mutationally-
activated KRAS perturbs apical PRKCZ, impairs 
multicellular organization and suppresses 1,25(OH)2D3 
rescue of Caco-2 ShPTEN gland morphology. 
Translational and human studies
To investigate relationships between polarity 
signalling and tumor morphology, we conducted 
histologic, immunohistochemical or RNAscope in situ 
hybridization studies in murine or human intestinal 
tumors. We used an intestinal epithelial-specific PTEN 
knockdown murine model [34] to investigate morphology 
of intestinal cancers driven purely by PTEN-deficiency. 
Two small intestinal cancers developed after a long 
latency and showed cribriform morphology (Figure 6A). 
In whole sections of 35 human CRCs in cohort (i), CM 
was heterogeneously distributed and affected > 50% 
glandular structures in 11.3 ± 8.5/40 fields per tumor. CM 
involved < 20% CRC surface area and was detected at 
low power (LP) (x3) magnification in 19/35 CRC whole 
tumor sections (54%). In TMA studies of cohort (ii), CM 
was detected at LP microscopy in 131/306 CRC cores 
(43%) from 92 CRCs. CM was more frequent in grade 
I and II CRCs in both study cohorts (Supplementary 
Figure S6A). Thirty six CRCs were mutated at KRAS 
exons 12 or 13 while 56 had wt KRAS. PTEN mRNA and 
protein expression were assayed by RNAScope [35] and 
immunohistochemistry (IHC) respectively. SLC9A3R1 
IHC assays were also conducted as readout of apical 
PRKCZ activity [36]. We found that log-transformed 
PTEN RNAscope values (Supplementary Figure S6B), 
PTEN IHC and SLC9A3R1 IHC scores all correlated in 
human CRC (PTEN RNA vs PTEN IHC, r = 0.33; p < 
0.01; PTEN RNA vs SLC9A3R1 apical intensity r = 0.36; 
p < 0.01; PTEN IHC vs SLC9A3R1 apical intensity r = 
0.28; p < 0.01 Figure 6B). Apical SLC9A3R1 intensity 
directly associated with CM in all CRCs (Figure 6C) but 
PTEN RNA expression associated with CM only in the 
KRAS wt subset (Figure 6D). Apical SLC9A3R1 intensity 
had prognostic significance and inversely associated with 
histological grade (Figure 6E) and lymph node metastasis 
(Figure 6F). 
Collectively, the above translational studies support 
the utility of 3D organotypic models for investigation 
of multiscale development of cancer morphology. As 
a manifestation of well- and moderately-differentiated 
CRC, CM associates with defective AP signalling and may 
represent an early or intermediate stage in a trajectory of 
cancer dedifferentiation (Supplementary Figure S6C). 
DISCUSSION
PTEN modulates the highly conserved apical 
CDC42-PRKCZ-PARD polarity complex [11, 12] that 
has a pivotal role in mitotic spindle orientation [7, 10, 
29, 37], organization of epithelial architecture and tissue 
homeostasis [38]. PTEN regulates spindle orientation in 
nonpolarized cultured cells [13] and in this study we show 
PTEN regulation of spindle alignment in polarized Caco-
2 cells during formation of simple colorectal glandular 
structures. Conversely, PTEN-deficiency induced spindle 
misorientation, epithelial stratification, apical membrane 
misalignment and formation of multiple abnormal 
lumens characteristic of cribriform morphology (CM). 
Furthermore, development of CM in Caco-2 ShPTEN 
glands associated with increased gland cellularity and 
size, in accord with loss of PTEN antiproliferative activity 
[39]. SiRNA knockdown of PTEN also induced cribriform 
architecture in a different CRC cell type (SK-CO-15) that 
has the capacity for 3D organotypic growth [40]. Our 
findings thus provide a mechanistic template for PTEN 
regulation of mitotic spindle alignment, growth of simple 
or stratified epithelium, AM dynamics and organization of 
colorectal multicellular architecture. 
Downstream of PTEN, the CDC42-PRKCZ-PARD 
apical complex [11] tightly orchestrates spindle dynamics 
[9] and cell polarization [10]. PARD3 is essential for 
recruitment of PRKCZ to the apical surface, formation 
of the PARD3-PRKCZ-PARD6 complex and for CDC42 
activation of PRKCZ [38]. These molecular interactions are 
implicated in multiple processes of epithelial organization 
[10]. Robust functional readouts of apical PRKCZ activity 
are provided by signal intensities of phospho-PRKCZ [9] 
or SLC9A3R1 [36] at the apical domain. In this study, 
high apical p-PRKCZ or SLC9A3R1 intensities in wt 
Caco-2 glands associated with appropriate subapical 
PARD3 localization, correct spindle alignment and regular 
gland morphology. Conversely in PTEN-deficient Caco-
2 ShPTEN glands, we found reduced apical p-PRKCZ 
and SLC9A3R1 intensities, PARD3 mislocalization, 
spindle misalignment and aberrant multicellular glandular 
architecture. Hence, PTEN regulates components of the 
CDC42/PRKCZ/PARD apical polarity complex to control 
spindle orientation and 3D gland morphology. 
Spindle microtubule regulatory kinases are 
controlled by nuclear PTEN [41] and nuclear import of 
PTEN is Ca2+-dependent [42]. Because 1,25(OH)2D3 
may enhance PTEN expression [16] and promotes rapid 
Ca2+ signalling in a VDR-dependent manner [18], we 
tested effects of this secosteroid upon spindle regulatory 
machinery and gland morphology. 1,25(OH)2D3 
upregulated VDR expression and enhanced VDR nuclear 
localization in Caco-2 and Caco-2 ShPTEN cells, 
indicating Vit-D responsiveness of the model system. In 
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Caco-2 ShPTEN cells, 1,25(OH)2D3 treatment enhanced 
PTEN expression, increased CDC42-GTP levels, enhanced 
apical p-PRKCZ intensity and restored mitotic spindle 
orientation to levels comparable with wt Caco-2 cultures. 
1,25(OH)2D3 treatment suppressed CM by restoring 
formation of epithelial monolayers and single lumens in 
Caco-2 ShPTEN glands for the total sustainable interval 
of 3D culture growth (20 days). Conversely, cessation 
of 1,25(OH)2D3 treatment enabled rapid reappearance of 
CM. Vit-D has antiproliferative properties [43] and in 
this study, 1,25(OH)2D3 treatment also suppressed Caco-
2 ShPTEN gland cellularity. While previous studies of 
1,25(OH)2D3 regulation of cribriform morphology are 
lacking, this secosteroid has been shown previously to 
suppress epithelial stratification in a human epidermis 
culture model [24] and promoted a symmetrical, circular 
shape of MCF10DCIS mammospheres [23]. 
The PTEN/CDC42-PRKCZ-PARD apical complex 
regulates a repertoire of morphogenic processes [10, 
11, 29, 38]. We functionally dissected this signal 
transduction cascade to identify principal 1,25(OH)2D3-
dependent effectors. While 1,25(OH)2D3 upregulated 
PTEN, it also rapidly activated CDC42 by PTEN-
independent mechanisms and enhanced apical p-PRKCZ 
and SLC9A3R1 signal intensities. Disruption of Caco-2 
glandular morphogenesis by DN CDC42 transfection 
or treatment with an allosteric PRKCZ pseudosubstrate 
inhibitor (PRKCZ I), as described previously [7, 29, 36], 
could not be reversed by 1,25(OH)2D3. Furthermore, 
restorative effects of 1,25(OH)2D3 on Caco-2 ShPTEN 
gland morphology were blocked by PRKCZI treatment. 
Collectively, these findings implicate CDC42 and/or 
PRKCZ signalling in 1,25(OH)2D3 regulation of gland 
morphology. 
Mitotic spindle machinery is governed in part 
by steroid hormone signalling [44]. 1,25(OH)2D3 is a 
multipotent secosteroid that regulates gene transcription 
and also induces rapid Ca2+ flux through L-type voltage-
dependent Ca2+ channels (LTVDCCs) [31] and CaM-KII 
mediated release of Ca2+ from intracellular stores [32]. Ca2+ 
flux and CaM-KII signalling initiate juxtamembrane signal 
transduction [45], activate CDC42 [19, 20] and modulate 
microtubule dynamics [21]. In this study, 1,25(OH)2D3 
treatment enhanced intracellular Ca2+ concentration in 
Caco-2 cells that expressed LTVDCCs in basolateral 
membranes, as previously described [46]. 1,25(OH)2D3 
treatment upregulated CDC42 activity within minutes but 
took up to 24 hrs to enhance PTEN expression in Caco-
2 cells. Furthermore, 1,25(OH)2D3 treatment upregulated 
CDC42-GTP in both PTEN +/+ and PTEN -/- HCT116 
colorectal cells. SiRNA VDR knockdown, blockade of 
LTVDCCs by NF treatment or inhibition of CaM-KII by 
KN-93 all suppressed 1,25(OH)2D3-mediated activation of 
CDC42. SiRNA knockdown of VDR or treatment with NF 
or KN-93 also blocked 1,25(OH)2D3-mediated activation 
of CDC42 and reversal of CM in Caco-2 ShPTEN glands. 
Taken together, these data implicate VDR, LTVDCC 
- and CaM-KII -mediated Ca2+ flux in Vit-D control 
of multicellular morphology, through CDC42/PRKCZ 
signalling. 
Because mutant KRAS can impede Vit-D growth 
control [27, 47] and can modulate VDR signalling 
[29], we investigated its effects on 1,25(OH)2D3 pro-
morphogenic activity. Transfection of KRAS wt Caco-
2 cells [48, 49], with mutationally-activated KRAS V12 
suppressed uniform localization of active PRKCZ at the 
apical membrane interface and induced formation of 
solid, cell-filled Caco-2 glands that lack a central lumen, 
as previously reported [33]. Furthermore, KRAS V12 
antagonized 1,25(OH)2D3 rescue of Caco-2 ShPTEN gland 
morphology. Hence, mutationally-activated KRAS impedes 
PRKCZ apical localization, disrupts CRC multicellular 
architecture and inhibits Vit-D promorphogenic activity, 
in 3D models. 
To explore the translational relevance of our 
findings, we investigated tumor formation in an intestinal-
epithelial specific PTEN-deficient murine model [34] and 
assessed polarity signalling against CM in 2 human CRC 
cohorts. In the murine model, small intestinal cancers 
driven purely by PTEN-deficiency [34] developed CM. 
These findings accord with previous reports of CM in 
various cancers of PTEN-haploinsufficient mice [50]. 
In human studies of cohort (i), we found CM on low 
power microscopy in 54% CRCs and heterogenous 
CM distribution whole tumor sections. Because 
PTEN deficiency and mutationally-activated KRAS 
can synergistically co-regulate tumor morphology in 
transgenic mice [51], we studied a larger series of 92 
KRAS genotyped CRCs (cohort ii) and found CM on 
low power microscopy in 43% CRCs. CM associated 
with grade I and II CRCs in both cohorts, consistent 
with an early transition state during a trajectory of CRC 
dedifferentiation. In accord with previous findings [52], 
we found no relationship between PTEN expression and 
KRAS mutational status in human CRC. However, PTEN 
RNA directly associated with CM in KRAS wt tumors but 
not in the KRAS mutant CRC subgroup, nor in the total 
CRC series of cohort (ii). These findings suggest that 
PTEN-KRAS epistatic interactions may influence human 
CRC morphology. 
Downstream of PTEN, apical PRKCZ represents a 
central morphogenic effector within the apical polarity 
complex [11, 36]. Apical SLC9A3R1 intensity provides 
a robust readout of apical PRKCZ activity in 3D models 
[36] and can be reliably assessed in human formalin-fixed 
paraffin embedded (FFPE) colorectal specimens [36,53]. 
In cohort (ii) human CRCs, we found positive correlations 
between PTEN RNAscope, PTEN IHC and apical 
SLC9A3R1 IHC intensity. We and others have shown that 
apical SLC9A3R1 intensity [36, 53] and PTEN expression 
[54, 55] are substantively higher in normal colonic mucosa 
than in CRC [36, 53-55]. In CRCs of the present study, we 
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found higher expression of apical SLC9A3R1 intensity in 
cribriform as opposed to non-cribriform CRCs, consistent 
with CM as an early or intermediate stage in a trajectory of 
cancer dedifferentiation. A similar rationale may explain 
the higher PTEN RNA expression in cribriform CRC than 
in non-cribriform KRAS wt CRCs. 
Compelling experimental, epidemiological and 
clinical data show that Vit-D controls inception and 
progression of CRC [25, 26]. However, there is a 
fundamental gap between discovery of Vit-D anticancer 
activity and identification of mechanistic biomarkers 
needed to exploit its full clinical potential. Strikingly, 
our findings show that 1,25(OH)2D3 controls subcellular, 
cellular and multicellular scales of tissue assembly to 
suppress CM. Hence, 1,25(OH)2D3 anticancer effects 
may be mediated in part by Ca2+/CaM-KII-dependent 
reprogramming of polarization machinery to suppress 
oncogenic disruption of homeostatic multicellular 
architecture. Our study shows that KRAS mutation 
indicates Vit-D-resistance. Conversely, apical SLC9A3R1 
intensity provides readout of PRKCZ [36] a key 
morphogenic effector of the PTEN/CDC42/PRKCZ 
pathway [11], has prognostic relevance in human CRC 
and predicts 1,25(OH)2D3 control of gland morphology. 
Apical SLC9A3R1 intensity is suppressed by mutationally-
activated KRAS in 3D models and associates with CM in 
both KRAS mutant and wt human CRCs. 
Globally, cancer affects over 12 million new 
patients each year [56]. Cancer morphology has been a 
gold-standard for diagnosis and outcome prediction since 
the time of Virchow [57] but has remained a mechanistic 
“black box” with few advances and almost no literature 
exploring its pathobiology. Our MS now untangles the 
molecular framework of cribriform morphology in 3D 
CRC models, shows Vit-D suppression of CM evolution 
via core polarization machinery and conducts translational 
and clinical studies that support model predictions. 
We also identify biomarkers of Vit-D resistance (KRAS 
mutation) and promorphogenic effects (apical SLC9A3R1) 
for use in future clinical trials. 
MATERIALS AND METHODS
Reagents and antibodies
Laboratory chemicals were purchased from 
Sigma-Aldrich, Dorset, England unless otherwise stated. 
Antibodies included mouse anti-PTEN (Cell Signaling, 
Danvers, MA, USA and Dako anti-PTEN clone 6H2.1), 
mouse anti-SLC9A3R1, Lifespan Biosciences, Seattle, 
WA, USA), anti-CDC42 and anti-CTNNB1 (also known 
as β-catenin - Cell Signaling, Danvers, MA, USA), anti-
CaV1.3 antibody against the α subunit of LTVDCCs [58], 
anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase 
(ab8245); anti-VDR (ab54373) and rabbit anti-phospho-
PRKCZ [Thr 560] (all from Abcam Cambridge, MA, 
USA). For confocal microscopy, primary antibodies were 
used in conjunction with Alexa Fluor 568 (anti-rabbit) 
and Alexa Fluor 488 (anti-mouse; Molecular probes, 
Invitrogen, Carslbas, CA, USA). 
Cell lines
Stable PTEN-deficient Caco-2 ShPTEN cells 
were generated by transfection of parental Caco-2 cells 
with replication-defective retroviral vectors encoding 
PTEN short hairpin RNA (shRNA), using the Phoenix™ 
retroviral expression system (Orbigen, San Diego, 
CA USA), as previously described [12, 36]. Transient 
SiRNA PTEN knockdown was conducted in SK-CO-15 
colorectal cells (gift from Dr F Real, Madrid) that have 
the capacity for 3D organotypic growth [40]. PTEN +/+ 
and PTEN -/- HCT116 cells were used in signalling assays, 
as previously described [59]. Caco-2 clones and SK-
CO-15 cells were propagated in two-dimensional (2D) 
cell culture flasks in MEM (modified Eagle’s medium) 
supplemented with 10% FCS, 1mM non- essential amino 
acids and 1mM L-glutamine at 37°C in 5% CO2. PTEN +/+ 
and PTEN -/- HCT116 cells were cultured in McCoys 5A 
media supplemented with 10% FCS, 1mM L-glutamine 
and 1mM sodium pyruvate, as previously described [12, 
36]. 
Three-dimensional (3D) cultures
Development of multicellular architecture was 
assessed in PTEN-expressing Caco-2, PTEN-deficient 
Caco-2 ShPTEN cells, parental PTEN-expressing SK-
CO-15 cells and a subclone rendered PTEN-deficient 
by SiRNA knockdown, in organotypic cultures. Cells 
were cultured and embedded in Matrigel matrix (BD 
Biosciences, Oxford, UK), then imaged by confocal 
microscopy during progressive development of 
multicellular glandular architecture, as previously 
described [12, 36]. SK-CO-15 cells express apical 
membrane markers at low level [60] and apical SLC9A3R1, 
PRKCZ or p-PRKCZ were undetected in these cells, in 
this study. Cribriform morphology (CM) was defined 
as multiple aberrant lumens surrounded by abnormal 
stratified epithelium in 3D multicellular structures in 
culture and in tumors [6]. Effects of transfections or 
treatments on glandular morphology of 3D cultures were 
assessed against endpoints of CM or individual features of 
epithelial configuration (columnar or stratified) or single 
central lumen formation. 
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Transfections and treatments
Caco-2 and/or Caco-2ShPTEN 3D cultures were 
transfected with mutant CDC42 constructs, as previously 
described [12, 36] and/or treated by 1,25(OH)2 D3 (10-7M), 
inhibitors of L-type calcium channels (nifedipine) [61], 
calcium calmodulin-dependent protein kinase II (CaMKII) 
[KN-93] [62] or a myristoylated PRKCZ pseudosubstrate 
peptide containing a membrane-targeting myristoylation 
tag that functions as an effective PRKCZ pseudosubstrate 
inhibitor (PRKCZI) [63].
Intestinal-epithelial specific PTEN-deficient 
murine model
All animal procedures were conducted in 
accordance with local and national regulations. Mice 
were generated, housed, and genotyped, and Cre activity 
was induced as previously described [34]. A total of 30 
Ah::CreERTT+/0;PtenF/F mice and 29 Ah::CreERTT+/0;Pten+/+ 
mice were enrolled into cohorts for prolonged follow up. 
Tissues were harvested, fixed, and processed according to 
standard protocols, as previously described. [34].Animals 
were monitored closely for symptoms of disease, and 
were then necropsied as previously described [34]. The 
morphology of tumors arising in PTEN-deficient murine 
intestinal epithelium was assessed by H&E histology. 
Cribriform morphology was assayed as previously defined 
[6]. 
Human colorectal cancer studies
We conducted 2 separate studies of polarity 
signalling against cribriform morphology (CM) in human 
colorectal cancer (CRC). We used anonymised formalin 
fixed, paraffin embedded (FFPE) samples from (i) 35 
patients with non-genotyped CRCs and (ii) 92 patients 
with KRAS-genotyped CRCs. We assessed CM at low 
power microscopy according to previously defined criteria 
[6] in both study cohorts. To assess CM heterogeneity, we 
scored CM in 40 fields per tumor at 20x magnification 
across whole tumor sections in cohort (i). Scores of 0, 
1 and 2 were given for CM involvement of < 10%, 11-
50% and > 50% CRC epithelium per field. In cohort (ii), 
specimens were arranged in tissue microarrays (TMAs). 
To assess polarity signalling in CRC FFPE specimens, 
we assessed PTEN RNA expression by RNAscope in 
situ hybridization [35]. We assessed apical SLC9A3R1 
intensity by immunohistochemistry (IHC) as readout of 
apical PRKCZ activity as outlined previously [36], in 
FFPE specimens of both study cohorts. To assess PTEN 
protein expression, PTEN IHC was also assessed in cohort 
(ii) TMAs. Samples used in this research were released 
from the Northern Ireland Biobank (NIB13-0090), 
approved by the Office of Research Ethics Committees 
Northern Ireland (Reference number 11/NI/0013/-/NIB13-
0090). 
Data analysis
Descriptive statistics were expressed as the mean ± 
sem. Statistical analyses were by one or two-way ANOVA 
or Student’s t test using SPSS for Windows release 22.0 
(IBM Corp, NY, USA) or Graphpad Prism software 
(v4.02; Graphpad CA 92037 USA). Scatterplots and bar 
charts were used for display of quantitative numerical or 
categorical data. PTEN RNA values were log transformed 
to provide a normal distribution.
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